Thrivent Financial for Lutherans increased its stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 7.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,863,930 shares of the company's stock after buying an additional 404,811 shares during the period. Thrivent Financial for Lutherans owned 3.45% of Option Care Health worth $183,541,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of OPCH. Envestnet Portfolio Solutions Inc. raised its stake in Option Care Health by 14.5% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 6,798 shares of the company's stock worth $228,000 after buying an additional 861 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Option Care Health by 4.6% during the first quarter. ProShare Advisors LLC now owns 38,774 shares of the company's stock valued at $1,300,000 after buying an additional 1,696 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of Option Care Health during the first quarter valued at approximately $267,000. SageView Advisory Group LLC purchased a new stake in shares of Option Care Health during the first quarter valued at approximately $85,000. Finally, Ontario Teachers Pension Plan Board grew its holdings in shares of Option Care Health by 48.5% during the first quarter. Ontario Teachers Pension Plan Board now owns 18,350 shares of the company's stock valued at $615,000 after buying an additional 5,997 shares during the last quarter. 98.05% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group cut shares of Option Care Health from a "buy" rating to a "neutral" rating and cut their price target for the company from $38.00 to $27.00 in a report on Monday, November 4th. Jefferies Financial Group cut shares of Option Care Health from a "buy" rating to a "hold" rating and dropped their target price for the stock from $38.00 to $26.00 in a report on Thursday, October 31st. Bank of America cut shares of Option Care Health from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $43.00 to $29.00 in a report on Wednesday, October 30th. Truist Financial dropped their target price on shares of Option Care Health from $41.00 to $34.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Finally, JMP Securities raised their target price on shares of Option Care Health from $36.00 to $37.00 and gave the stock a "market outperform" rating in a report on Monday, September 30th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $30.83.
Get Our Latest Report on OPCH
Insider Transactions at Option Care Health
In other news, Director Elizabeth Quadros Betten sold 47,531 shares of the firm's stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $31.09, for a total transaction of $1,477,738.79. Following the sale, the director now directly owns 21,339 shares in the company, valued at $663,429.51. This trade represents a 69.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael H. Shapiro sold 23,217 shares of the firm's stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.95, for a total transaction of $718,566.15. Following the sale, the chief financial officer now owns 247,317 shares in the company, valued at $7,654,461.15. The trade was a 8.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.64% of the company's stock.
Option Care Health Stock Performance
Shares of Option Care Health stock traded down $0.26 on Friday, hitting $21.93. 1,974,267 shares of the company's stock were exchanged, compared to its average volume of 2,698,041. The company has a 50-day simple moving average of $28.62 and a 200-day simple moving average of $29.37. The stock has a market capitalization of $3.73 billion, a PE ratio of 18.43, a PEG ratio of 2.27 and a beta of 1.32. Option Care Health, Inc. has a 1 year low of $21.64 and a 1 year high of $34.63. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73.
Option Care Health Profile
(
Free Report)
Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
Further Reading
Before you consider Option Care Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Option Care Health wasn't on the list.
While Option Care Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.